Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Beumont

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Clinical Pharmacokinetics|November 30, 2016
Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic ModellingJan Snoeys, Maria Beumont, Mario Monshouwer, et al.
Clinical Pharmacokinetics|September 11, 2015
Drug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirSivi Ouwerkerk-Mahadevan, Jan Snoeys, Monika Peeters, et al.
Antiviral Therapy|January 25, 2013
Review of drug interactions with telaprevir and antiretroviralsRolf P G van Heeswijk, Maria Beumont, Robert S Kauffman, et al.
The Lancet. Infectious Diseases|October 31, 2024
Predictable excess hepatotoxicity in the SimpliciTB trial - Authors' replyMuge Cevik, Maria Beumont, Eugene Sun, et al.
Virology Journal|June 3, 2014
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirSandra De Meyer, Anne Ghys, Inge Dierynck, et al.
Antimicrobial Agents and Chemotherapy|March 11, 2025
Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participantsAntonio Lombardi, Fran Pappas, Paul Bruinenberg, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2024
Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjectsAntonio Lombardi, Fran Pappas, Jerry Nedelman, et al.
BMC Infectious Diseases|August 29, 2014
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infectionJane Scott, Kathleen Rosa, Min Fu, et al.
Drugs in R&D|August 8, 2015
Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal ImpairmentSivi Ouwerkerk-Mahadevan, Maria Beumont-Mauviel, Steven Mortier, et al.
The Journal of Infectious Diseases|June 27, 2013
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trialYves Benhamou, Joseph Moussalli, Vlad Ratziu, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Clinical Pharmacokinetics|November 30, 2016
Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic ModellingJan Snoeys, Maria Beumont, Mario Monshouwer, et al.
Clinical Pharmacokinetics|September 11, 2015
Drug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirSivi Ouwerkerk-Mahadevan, Jan Snoeys, Monika Peeters, et al.
Antiviral Therapy|January 25, 2013
Review of drug interactions with telaprevir and antiretroviralsRolf P G van Heeswijk, Maria Beumont, Robert S Kauffman, et al.
The Lancet. Infectious Diseases|October 31, 2024
Predictable excess hepatotoxicity in the SimpliciTB trial - Authors' replyMuge Cevik, Maria Beumont, Eugene Sun, et al.
Virology Journal|June 3, 2014
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirSandra De Meyer, Anne Ghys, Inge Dierynck, et al.
Antimicrobial Agents and Chemotherapy|March 11, 2025
Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participantsAntonio Lombardi, Fran Pappas, Paul Bruinenberg, et al.
Antimicrobial Agents and Chemotherapy|August 28, 2024
Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjectsAntonio Lombardi, Fran Pappas, Jerry Nedelman, et al.
BMC Infectious Diseases|August 29, 2014
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infectionJane Scott, Kathleen Rosa, Min Fu, et al.
Drugs in R&D|August 8, 2015
Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal ImpairmentSivi Ouwerkerk-Mahadevan, Maria Beumont-Mauviel, Steven Mortier, et al.
The Journal of Infectious Diseases|June 27, 2013
Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trialYves Benhamou, Joseph Moussalli, Vlad Ratziu, et al.
Pageof 5